Background Distal renal tubular acidosis (dRTA) is characterized by hyperchloraemic metabolic acidosis, hypokalaemia, hypercalciuria and nephrocalcinosis. It is due to reduced urinary acidification by the α-intercalated cells in the collecting duct and can be caused by mutations in genes that encode subunits of the vacuolar H +
Introduction
Distal renal tubular acidosis (dRTA), also often referred to as type 1 RTA, is caused by a decreased capacity of the α-intercalated cells in the collecting duct to excrete protons. Biochemically, this disorder is characterized by a hyperchloraemic metabolic acidosis with normal plasma anion gap, hypokalaemia and hypercalciuria with hypocitraturia causing nephrocalcinosis. Despite a profound metabolic acidosis, patients are unable to acidify their urine and will have a urinary pH of >5.5 [1, 2] .
Patients often present with vomiting, diarrhea or constipation, failure to thrive and/or rickets. Severe hypokalaemia can cause muscle weakness or paralysis [2] . Chronic acidosis leads to bone demineralization which can result in rickets and/or stunted growth in children with dRTA. The excess of calcium that is released into the blood stream, combined with the decreased expression of renal calcium transporters in metabolic acidosis, causes hypercalciuria [3, 4] . This hypercalciuria in turn can result in nephrocalcinosis and, if left untreated, to renal calculi formation. Polyuria due to an impaired urinary concentrating ability (secondary nephrogenic diabetes insipidus) is another typical feature and may be related to electrolyte abnormalities in blood and/or urine and the nephrocalcinosis [5] .
To date, several genes are known to cause dRTA. Autosomal recessive inheritance is noted in mutations in ATP6V1B1 and ATP6V0A4, genes encoding subunits of the vacuolar H + -ATPase, and sometimes in SLC4A1, the gene encoding anion exchanger 1. Mutations in the latter gene, however, generally cause the autosomal dominant form of dRTA [1] .
In this study we present data on children with dRTA followed in our outpatient clinic over the last 20 years, including all available data from DNA analysis.
Patients and methods
This is a single-centre, retrospective study on the molecular diagnosis and clinical follow-up of children with dRTA who were followed in the specialized tubulopathy outpatient clinic of Great Ormond Street Hospital (London, UK) during the last 20 years. Distal renal tubular acidosis was defined as hyperchloraemic metabolic acidosis with a normal plasma anion gap, with inappropriately high urinary pH on repeated sampling. All parents of children with dRTA were offered genetic analysis to confirm the diagnosis. Clinical and biochemical data were retrieved from the patients' medical records and included details until transition into adult services. The estimated glomerular filtration rate (eGFR) was measured using the bedside Schwartz formula [6] .
Results
In total 24 patients were included in the study, with a median follow-up of 10 (range 1-18) years. Clinical details are presented in Table 1 . The molecular diagnosis was confirmed in 19 patients, of whom six had homozygous or compound heterozygous mutations in ATP6V1B1, ten had mutations in ATP6V0A4 (including one pair of siblings) and three had mutations in SLC4A1. We found five mutations which had not been previously reported, namely, two mutations in 15] . In patient 20 only one mutation was found in ATP6V0A4. Although this mutation was predicted to be pathogenic, patient 20 was not considered to have a confirmed molecular diagnosis since mutations in this gene have an autosomal recessive pattern of inheritance. Patients 5 and 15 were seen in our clinic for a second opinion; treatment strategies may therefore not necessarily represent the general practice in our hospital.
Disease presentation

Age at diagnosis
In general, the patients in our study with autosomal recessive mutations (patients 1-16 and patient 19) had a tendency to present earlier in life than those with an autosomal dominant form of dRTA (patients 17 and 18) . The children with autosomal recessive-inherited mutations presented at a median age of 3 months (range 2 weeks to 2 years and 2 months), with only three of the 17 children presenting after the age of 1 year. In contrast, both children with autosomal dominant mutations presented after the age of 1 year, at 1 year and 5 months and 4 years of age, respectively (Fig. 1) . This difference was statistically significant (p < 0.01, Student's t test).
Interestingly, patient 17 was assessed initially at the age of 1 year because of the family history of dRTA in both mother and maternal grandmother. Molecular diagnosis was not available in the family at the time and the initial clinical assessment was unremarkable, with normal plasma electrolytes (K + 4.3 mmol, HCO 3 20 mmol/L), normal venous pH (7.34), normocalciuria (calcium/creatinine ratio 0.36 mmol/mmol) and normal renal ultrasound. A diagnosis was not established at the time and only further observation was recommended. At 17 months of age, she had an episode of diarrhea, and subsequent blood tests revealed acidosis (venous pH 7.29, plasma HCO 3 16 mmol/L), with inappropriately elevated urine pH (7.5), revealing her to be affected, later confirmed by molecular diagnosis.
Presenting symptoms
Many children with dRTA presented with failure to thrive and growth retardation. This was most profound in the children with ATP6V1B1 mutations and in those in whom no genetic mutation could be found (Fig. 2) . Severe growth retardation according to the first documented measurement after presentation, with a height on or below −2 standard deviation score (SDS), was found in 12 children. Specifically, severe growth retardation was documented in four of the six children with mutations in ATP6V1B1, in three of the ten children with mutations in ATP6V0A4, in one of the three children twith SLC4A1 and in four of the five children without a confirmed genetic diagnosis. All children were found to have metabolic acidosis at initial presentation. However, given the retrospective nature of this study the exact blood pH at diagnosis could only be recovered from the medical records in nine patients, all of whom had a blood pH at diagnosis of <7.25. Serum bicarbonate levels at diagnosis, however, could be recovered in the majority of patients and were well below 18 mmol/L. Both blood pH and serum bicarbonate levels were the lowest in children with mutations in ATP6V0A4, with those children with mutations in SLC4A1 generally presenting with less severe acidosis (Fig. 3) . Two-thirds of our patients presented with features of partial renal Fanconi syndrome. Fourteen children had tubular proteinuria, eight children had a decreased tubular resorption of phosphate (TRP) and five patients showed mild generalized aminoaciduria. None of the children had glycosuria. Surprisingly, at first presentation, only seven children had an elevated urinary calcium/creatinine ratio. However, these measurements were performed on spot urine samples, and patients were polyuric, which in our laboratory can result in inaccuracies in the determination of creatinine in urine, as the assay is optimized for higher creatinine concentrations. A formal 24-h urine calcium determination would have been more informative, but such measurements are difficult to obtain in non-toilet trained children without catheterization.
All patients except for patient 17 had nephrocalcinosis at first presentation. The first ultrasound in patient 5 was performed abroad and the report could not be retrieved. Patient 17 had a family history of autosomal dominant dRTA (her mother and grandmother) and was screened before the onset of symptoms. In the other children for whom ultrasound results were available at the moment of diagnosis, nephrocalcinosis was reported by the radiologist to be mild (increased echogenicity in the borders of the pyramids) in ten patients, moderate (diffuse, increased echogenicity of the entire pyramids) or moderate to marked in four children and marked (homogenous, increased echogenicity of the entire pyramids, often in the presence of acoustic shadowing) in eight patients. Only three children developed renal calculi (patients 10, 19 and 23), none of whom required medical intervention. There was no correlation between the development of renal calculi and the degree of nephrocalcinosis at first presentation (marked in patient 10 and 23 and mild in patient 19).
Treatment
Treatment with alkali (bicarbonate and/or citrate) was started at a median age of 4 months (range 2 weeks to , and the mean of all patients is depicted on the right (All) Fig. 1 Boxplot of age (in months) at onset of alkali treatment according to the different genotypes (ATP6V1B1, ATP6V0A4, SLC4A1, Unknown) and for all patients (All). Thick horizontal line in box Median, top, bottom of box first, third quartile, respectively, whiskers maximum-minimum higher alkali doses than children with mutations in the gene that encodes anion exchanger 1 (SLC4A1), (Fig. 4) . Thiazide diuretics were administered to three patients. In patient 8, thiazides were started at the age of 2 months and stopped after 2 years; in patient 9, thiazides were started at the age of 1 month and stopped 1 month later. In both of these children, treatment with thiazides was started in the referring centres. Patient 23 was started on thiazide treatment at the age of 11 years after two episodes of flank pain that resolved after passing concrements and remained on thiazides into adulthood.
Patient 15 was started on indomethacin by the referring team at the age of 6 months because of severe polyuria with the possible diagnosis of renal Fanconi syndrome. After the diagnosis of dRTA therapy with indomethacin was stopped at the age of 2 years but subsequently restarted due to worsening of polyuria.
Clinical features at last follow-up
Growth parameters
After the start of alkali treatment, there was a clear improvement in the growth parameters in most children. Sustained growth retardation, with a height on or below −2 standard deviation score (SDS) on the most recent measurement, was documented in only three children, while the overall height SDS had improved in all groups. A similar improvement in weight SDS was found (Fig. 2) . There was no clear correlation with growth retardation at the most recent follow-up and the age of therapy onset (2 months, 9 months and 5.3 years, respectively) or gene mutation (ATP6V0A4, SLC4A1 and unknown). Of the three children with sustained growth retardation, one had a normal renal function with an eGFR of 152 mL/min/1.73 m 2 , and the other two had chronic kidney disease (CKD) stage 2 with an eGFR of 67 and 70 mL/min/ 1.73 m 2 , respectively.
Chronic kidney disease
Renal insufficiency was found in nine of the 24 children, all of whom had an eGFR of 60-90 mL/min/1.73 m 2 , consistent with CKD stage 2. There was no clear correlation with renal function and genetic diagnosis: decreased renal function was found in one of the six patients with mutations in ATP6V1B1, in five of the ten patients with ATP6V0A4 mutations, in one of the three patients with SLC4A1 mutations and in two of the five children who had no confirmed genetic diagnosis.
Radiological features
Medullary cysts were reported on the most recent renal ultrasound in nine of the 24 children. The age at which the first cysts were noted ranged between 3 and 17 years. Two of the three patients who developed renal calculi had medullary cysts, but there was no correlation between the development of medullary cysts and the degree of nephrocalcinosis at diagnosis (which was mild in 5 patients with medullary cysts, moderate in 1 patient and marked in another 3 patients). Also, there was no clear effect of the presence of medullary cysts on renal function, which was normal in three of the patients with renal cysts while the remaining six patients had CKD stage 2. Of the ten patients with ATP6V0A4 mutations four developed cysts, all after the age of 10 years. Two out of the three patients with mutations in SLC4A1 developed cysts, one at age 4 years and the other at age 17 years. No molecular diagnosis could be made in the remaining three patients that developed medullary cysts, all of whom were below the age of 10 years when the cysts were first noted. There was no apparent correlation between the degree of nephrocalcinosis and the development of CKD.
Hearing
Hearing loss was documented in 11 children, including all children with ATP6V1B1 mutations. The hearing problems were found to be sensorineural in origin in six patients, five of whom had documented mutations in ATP6V1B1. In the sixth child no causative mutations were found. Three children were diagnosed with conductive hearing loss. This was attributed to recurrent ear infections in two of the children and improved over time; in the other child no mutation was found. Another   Fig. 4 Boxplot of alkali treatment (biocarbonate dose in mmol bicarbonate/kg/day) according to age of patient (1, 5, 10, 15 years). Alkali requirement is presented separately per genotype (ATP6V1B1, ATP6V0A4, SLC4A1, Unknown) and for all patients (All) two children were found to have combined sensorineural and conductive hearing problems, one of whom had a mutation in ATP6V0A4 and the other one in SLC4A1.
Discussion
We present clinical data on the follow-up of 24 children with dRTA in a single centre, including available data on genetic analysis. Although the sample size is rather small, this study contains valuable data on the long-term follow-up of patients with a rare disease. The majority of patients were followed for a long period of time, with 20 patients followed for at least 5 years and 12 patients for at least 10 years. The addition of molecular diagnostics data enabled us to compare the clinical phenotype with the molecular genotype. Moreover, the analysis of clinical data informs the prognosis and management of patients with this rare disease.
We found five mutations that to our knowledge are new to the literature. Publication of these will help to establish the diagnosis in other patients found to carry these mutations.
Treatment
The administration of alkali is the cornerstone of the treatment of dRTA. Due to growing children having a higher metabolic rate and protein intake than adults, they may need relatively higher treatment doses than the latter when corrected for body weight to maintain a normal pH. This need for increased biocarbonate doses was previously reported in a historical study in which five children with dRTA were followed for a period of <10 years [7] . Where adults in general require 0.5-1 mEq/kg/day of bicarbonate, this can be up to 5-8 mEq/kg in children [1] . The fact that younger children in general need higher doses of alkali was confirmed in our study. Moreover, children with mutations interrupting the function of the vacuolar H + -ATPase generally needed higher doses of alkali than those with mutations in SLC4A1 (Fig. 4) , and prescribed doses were typically highest at therapy onset. This is in line with the finding that children with mutations in ATP6V0A4 in general had a lower blood pH and lower serum bicarbonate levels at diagnosis (Fig. 3) . In cases with severe hypokalaemia, potassium supplements may also be warranted. In these patients, the prescription of potassium citrate or potassium bicarbonate can prove to be an elegant way to administer both.
Thiazide diuretics are sometimes used to decrease urinary calcium excretion, but they can in turn increase the risk of hypokalaemia and polyuria and are thus not routinely used in our centre. In our cohort of 24 patients, only three children developed small calculi, with none of them needing an intervention. Moreover, urinary calcium excretion is increased in acidosis and decreases after the administration of alkali [7, 8] . This makes it a good marker for adherence to and/or adequacy of treatment, but it may no longer be reliable after the administration of thiazide diuretics. Thus, in our opinion the use of alkali treatment, sometimes with additional potassium supplements, is sufficient to treat the majority of children with dRTA.
The experience with patient 17, in whom the routine biochemistries of plasma and urine were normal at the age of 12 months, suggests that a clinical diagnosis of dRTA cannot be excluded at such a young age in at-risk children and should ideally be established by molecular diagnostics, or, if this not possible, by clinical examination when the system is Bstressed^(for example after acid loading or, as in patient 17, during an episode of gastroenteritis with intestinal bicarbonate loss).
Associated symptoms
Interestingly, 16 of the 24 children in this study had features of renal Fanconi syndrome at presentation. The presence of such features indicates a proximal tubular dysfunction characterized by low-molecular-weight proteinuria (also referred to as tubular proteinuria), generalized aminoaciduria, hyperphosphaturia, glucosuria and increased urinary losses of bicarbonate (causing metabolic acidosis). Several other solutes that are reabsorbed in the proximal tubule can be lost as well [9, 10] . In our cohort, the 16 patients with partial renal Fanconi syndrome showed a combination of low-molecularweight proteinuria (measured as urinary retinol binding protein/creatinine ratio), increased urinary losses of phosphate (measured as TRP) and/or mild generalized aminoaciduria. Metabolic acidosis was obviously found in all patients, since this is a key feature of dRTA. However, none of the patients had full-blown renal Fanconi syndrome, since none of them showed glucosuria. In this way, the proximal tubulopathy resembles that of Lowe syndrome or Dent disease [11] . After initiation of alkali treatment, the features of renal Fanconi syndrome disappeared in all patients, establishing the correct diagnosis of dRTA in some children that had previously been diagnosed with renal Fanconi syndrome of unknown etiology. There have been several reports of children with dRTA presenting with partial renal Fanconi syndrome (low-molecularweight proteinuria, hyperphosphaturia and/or generalized aminoaciduria). As in our study, none of these children had glucosuria, and in all of them the proximal tubulopathy disappeared after treatment onset [7, [12] [13] [14] . The exact mechanism by which dRTA causes proximal tubular damage is unknown, but given the similarity of the tubulopathy with Dent disease/ Lowe syndrome it is tempting to speculate that this may be due to the impairment of similar pathways. Indeed, apart from those with unknown mutations the proximal tubulopathy was seen only in children with mutations in subunits of the vacuolar ATPase, which is expressed together with CLC-5 (the chloride transporter underlying Dent disease) in the lysosomes of the proximal tubule and α-intercalated cells [15] . However, why this lysosomal dysfunction would improve with correction of the acidosis is unclear, and the proximal tubulopathy may just reflect a general dysfunction due to the acidosis. From a clinical point of view, the key conclusion is to not prematurely exclude dRTA as a potential diagnosis in patients with a proximal tubulopathy, especially in young children with associated nephrocalcinosis. After correction of the acidosis and hypokalaemia, the abnormal markers of proximal tubular function should be monitored, since they will normalize in children with underlying dRTA.
In our population of 24 children with dRTA, the majority of patients (16 in total) had proven mutations in ATP6V1B1 (n = 6) and ATP6V0A4 (n = 10), interrupting the function of the vacuolar H + -ATPase. Both mutations can be associated with sensorineural hearing loss [1] . In fact, all six patients in our cohort who were found to have ATP6V1B1 mutations also had hearing loss, although this was conductive in origin in one child and was attributed to recurrent ear infections. Only one child with mutations in ATP6V0A4 was diagnosed with hearing loss: patient 13 was found to have a combined bilateral sensorineural and unilateral conductive hearing loss. Her sister, however, was not noted to have any hearing problems. Since both have the same mutation in ATP6V0A4, it remains unclear whether this mutation is in fact causing the hearing loss in patient 13. It has been noted in previous studies that hearing loss in children with ATP6V1B1 mutations generally presents before the age of 10 years, while hearing loss in patients with ATP6V0A4 mutations is often only diagnosed from the second decade of life onwards [16, 17] . The outcome in our cohort is in line with these findings, reinforcing the need for regular hearing examination in patients without any signs of deafness at diagnosis, since sensorineural hearing loss can still occur later in life.
One child (patient 19) in our patient cohort presented with the concomitant occurrence of Southeast Asian ovalocytosis and dRTA due to mutations in SLC4A1. The protein encoded by this gene is a polypeptide which forms a homodimer, to form the transporter AE1. The first deletion found in this patient is c.1199_1225del; p.(Ala400-Ala408del), which is a well-known mutation typically causing Southeast Asian ovalocytosis and in general occurs without a renal phenotype. Mutant non-functioning polypeptides form heterodimers with the wild-type polypeptide. The minimal net effect on the transport function of the newly formed protein results in the absence of a renal phenotype in the presence of a wild-type allele. However, this patient had a second mutation in her other allele, namely, c.2102G>A; p.(Gly701Asp), which gives rise to a mutant polypeptide that is trapped within the cell (probably in the Golgi apparatus), thus causing autosomal recessive dRTA. The presence of both mutations in one patient (one resulting in a non-functioning polypeptide and the other one resulting in a polypeptide being trapped intracellularly) causes autosomal recessive dRTA, while the c.1199_1225del mutation alone has been reported not to cause a renal phenotype [18, 19] . Although very rare, this combination of c.1199_1225del with c.2102G>A has been reported earlier to cause a combination of Southeast Asian ovalocytosis and dRTA [20] .
In this study, we found medullary cysts on the most recent renal ultrasound in 37.5% of our study population (9/24 patients). The development of medullary cysts in a subset of patients with dRTA has been well described [21] . The exact etiology of these cysts remains unclear, but again it was hypothesized that this may be caused by hypokalaemic nephropathy. In addition to the ischaemic changes, hypokalaemic nephropathy is associated with tubular hypertrophy and dilatation, which may cause renal cyst formation [22] . However, not all conditions with chronic hypokalaemia result in cyst formation. For instance, Bartter syndrome is often associated with severe chronic hypokalaemia, but medullary cysts are only rarely reported [23] . Moreover, in our population all patients developed cysts while receiving treatment. There was no correlation with the development of medullary cysts and the degree of nephrocalcinosis at diagnosis, nor with renal function at last follow-up. The development of medullary cysts is thus noted in a subset of patients with dRTA, but the clinical consequences remain limited in our cohort.
Conclusion
In general, the prognosis of dRTA is good when the diagnosis can be made early and if there is a good compliance to alkali treatment [2] . In this study, we did not find a correlation between the age at therapy onset or gene mutation and stunted growth or renal function. Nine patients were found to have CKD stage 2. Deterioration of renal function can be seen in patients with dRTA, mainly in those with hypercalciuria and recurrent renal stones, but progression into end-stage renal disease has only rarely been reported [24] . Growth retardation is often noted at diagnosis in children with chronic dRTA and is attributed to chronic metabolic acidosis. However, after the initiation of alkaline treatment catch-up growth can be noted [2, 7] , and in our study most children (87.5%) had a height within normal limits for age at the last follow-up, despite 50% of them showing profound failure to thrive at diagnosis (Fig. 2) . Thus, based on the results of our study we can confirm the general good prognosis of dRTA in children receiving alkali treatment.
In conclusion, we have presented clinical data on the longterm follow-up of 24 children with dRTA in a single centre, including available data on genetic screening and on five novel disease-causing mutations. All but one patient presented with the combination of metabolic acidosis and nephrocalcinosis, and 16 children had features of proximal tubular dysfunction which disappeared after initiation of treatment. The diagnosis of renal Fanconi syndrome should be made with care in children with severe metabolic acidosis and nephrocalcinosis at a young age; markers of proximal tubulopathy should be followed after initiation of treatment. Failure to thrive is often noted at diagnosis, and alkali treatment results in improved growth parameters in most children. Although their clinical relevance remains uncertain, we found medullary cysts, which are often reported in patients with dRTA, in six children. Hearing loss is also often associated with dRTA, mainly when mutations are documented in ATP6V1B1 or ATP6V0A4. In the latter gene, sensorineural deafness often develops in the second decade of life, warranting long-term follow-up of hearing in children with dRTA with normal initial hearing screening who have mutations in ATP6V1B1 and/or ATP6V0A4 or in whom no mutation was found. The basic treatment of dRTA consists in the prescription of alkali, if necessary combined with potassium supplementation. Although there was a tendency in the children in our study with ATP6V1B1 or ATP6V0A4 mutations to present earlier in life and to need higher doses of alkali, our study population was rather small, and we found no statistical significant correlation between gene mutation, age at therapy onset, growth parameters or renal function. Long-term studies that include genetic analysis in a bigger population, including data before and after transition into adult care, can further elaborate on the effects of early treatment onset and gene defects on final height, deterioration of renal function over time and the development of nephrocalcinosis with calculi and medullary cysts.
